

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(s): Jose Esteve-Soler, et al.

SERIAL NO.: 10/536,782 ART UNIT:

FILING DATE: 11/23/05 EXAMINER:

TITLE: USE OF 2, 5-DIHYDROXYBENZENESULFONIC COMPOUNDS  
FOR THE TREATMENT OF DISORDERS BASED ON AN  
IMPAIRMENT OF NO PRODUCTION AND/OR OF  
REGULATION OF EDHF FUNCTION

ATTORNEY

DOCKET NO.: 785-012246-US (PAR)

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT  
(37 C.F.R. §1.97(b)(3))

Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits.


The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following reference:

"Metabolisme et pharmacocinetique du dobesilate de calcium chez l'Homme<sup>(1)</sup>", A. Benakis, et al., Therapie, 1974, 29, 211-219

A copy of this reference is enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Respectfully submitted,



Geza C. Ziegler, Jr.  
Reg. No. 44,004

11 December 2004  
Date

PERMAN & GREEN, LLP  
425 Post Road  
Fairfield, CT 068424  
Customer No. 2512

